Kip1 (p27) controls cell cycle progression by binding to and inhibiting the activity of cyclin dependent kinases. Disruption of the p27 gene in mice (p277/7) results in increased body growth with a disproportionate enlargement of the spleen, thymus, testis, ovary and pituitary. The increase in pituitary size is due to selective hyperplasia of the intermediate lobe (IL) while the anterior lobe (AL) is not overtly aected. p27 heterozygous mice (p27+/7), as well as p277/7 mice, are hypersensitive to radiation-and chemical-induced tumors compared to wildtype (p27+/+) littermates. Therefore, unlike classical tumor suppressors, only a reduction in p27 levels is necessary to predispose tissues to secondary tumor promoters. Consistent with these studies is the fact that the p27 gene sequence and mRNA levels appear normal in human pituitary adenomas while p27 protein levels are decreased. Therefore, a reduction in p27 levels could be sucient to sensitize pituitary cells to tumorigenic factors. To test this hypothesis, metallothionein promoter-driven, human growth hormone-releasing hormone (MT-hGHRH) transgenic mice, that exhibit somatotrope hyperplasia before 9 months of age and subsequent adenoma formation with 30 ± 40% penetrance, were crossbred with p27+/7 mice for two successive generations to produce p27+/+, p27+/7 and p277/7 mice that expressed the hGHRH transgene. At 10 ± 12 weeks of age, p277/7 and p27+/+, hGHRH mice were larger than their p27+/+ littermates and displayed characteristic hyperplasia of the IL and AL, respectively. Expression of the hGHRH transgene in both p27+/7 and p277/7 mice selectively expanded the population of somatotropes within the AL, where pituitaries of p27+/7, hGHRH and p277/7, hGHRH mice were two-and ®vefold larger than p27+/+, hGHRH pituitaries, respectively. There was also a synergistic eect of hGHRH transgene expression and p27-de®ciency on liver, spleen and ovarian growth. At 6 ± 8 months of age, 83% of p27+/7, hGHRH mice displayed macroscopic AL adenomas (4100 mg), while all pituitaries from p27+/+, hGHRH mice remained hyperplastic (520 mg). In contrast to the dramatic eects of p27-de®ciency on hGHRH-induced organ growth, elimination of p53, by crossbreeding MT-hGHRH mice to p53-de®cient mice, did not augment the hyperplastic/ tumorigenic eects of hGHRH transgene expression.
Introduction
The cell cycle inhibitor, p27 Kip1 (p27), negatively regulates cell cycle progression in the G1/S transition phase by binding to and inactivating cyclin/cyclin dependent kinase (CDK) complexes Sherr and Roberts, 1999) . Mice with homozygous disruption of the p27 gene (p277/7) are 15 ± 30% larger than their heterozygous (p27+/7) and wildtype (p27+/+) littermates (Nakayama et al., 1996; Kiyokawa et al., 1996; Fero et al., 1996) . The increase in body weight is due to generalized organomegaly in addition to disproportionate enlargement of the spleen, thymus, testis, ovary and pituitary. The increase in pituitary size is con®ned to selective hyperplasia of the intermediate lobe while the anterior lobe is not overtly aected. With advancing age (46 months) p277/7 mice develop intermediate lobe tumors. In contrast to the tumorigenic eect of p27-de®ciency on intermediate lobe cells, hyperplasia of the spleen, thymus, testis and ovary does not progress to neoplasia under controlled environmental conditions. However, Fero and coworkers (Fero et al., 1998) recently reported that p27+/7 mice, as well as p277/7 mice, are more susceptible than are p27+/+ mice to both radiationand chemical-induced tumors of the lung, ovary and endometrium. These results indicate that a partial reduction in p27 can sensitize cells, in a tissue-speci®c manner, to external tumorigenic factors. Therefore, p27 is considered haplo-insucient for tumor suppression (Fero et al., 1998) .
The role of p27 in the initiation and progression of adenomas originating from the anterior pituitary is unclear. p27 gene mutations are rarely found in human pituitary tumors (Ikeda et al., 1997; Tanaka et al., 1997; Takeuchi et al., 1998; Dahia et al., 1998) and p27 mRNA levels are reported to be normal in many pituitary tumor subtypes (Tanaka et al., 1997; Takeuchi et al., 1998; Dahia et al., 1998) . However pituitary adenomas (LH/FSH, TSH, ACTH, GH/PRL and nonfunctioning) have lower levels of p27 protein compared to normal pituitary tissue Jin et al., 1997; Bamberger et al., 1999a; Lidhar et al., 1999) . This later observation suggests that a partial reduction in p27 levels, possibly due to abnormalities in post-transcriptional processing of the p27 gene, may be sucient to initiate or contribute to the progression of anterior pituitary tumor formation. To test this hypothesis in vivo, we examined the eects of partial reduction or complete elimination of p27 in a transgenic mouse model that develops pituitary tumors (somatotropinomas) in response to metallothionein promoter-driven, human growth hormone-releasing transgene expression (MT-hGHRH mice [Hammer et al., 1985; Mayo et al., 1988] ).
Results

Body weight
Growth rates of p27 intact mice, expressing the hGHRH transgene (p27+/+, hGHRH), exceeded those of their wildtype (p27+/+) littermates (P50.01; Figure 1 ). At 10 ± 12 weeks, male and female p27+/+, hGHRH mice were 25 and 28% larger than p27+/+ mice, respectively ( Figure 1 , and Table 1A ,B). In the absence of p27 (p277/7) growth rates were also accelerated and body weights achieved values similar to p27+/+, hGHRH mice. These observations are consistent with those reported for the original MThGHRH (Hammer et al., 1985; Mayo et al., 1988) and p277/7 (Nakayama et al., 1996; Kiyokawa et al., 1996; Fero et al., 1996) mouse strains, indicating that alterations in the genetic background did not signi®cantly alter the eect of hGHRH transgene expression or p27-de®ciency on body growth. Reduction or elimination of p27 (+/7 or 7/7) accelerated the growth promoting eects of the MT-hGHRH transgene in both male and female mice, with the most dramatic eects observed in p277/7, hGHRH mice ( Figure 1 ). By 12 weeks of age, p277/7, hGHRH male mice achieved 56.7+1.5 g and female mice achieved 58.8+1.5 g, almost twice as large as their wildtype littermates (Table 1A,B) .
Organ weights
The p277/7 mice in this study displayed generalized organomegaly with disproportionate enlargement of the spleen, pituitary, testis and ovaries (Table 1A ,B and Figure 2 ), as previously reported (Nakayama et al., 1996; Kiyokawa et al., 1996; Fero et al., 1996) . In p27+/+, hGHRH mice, as in the original MT-hGHRH mouse strain (Hammer et al., 1985; Mayo et al., 1988) , the pituitary, liver, spleen, heart and kidneys were increased in size, compared to their wildtype (p27+/+) littermates (Table 1A,B) , with disproportionate enlargement of the pituitary and liver (Figure 2) . Expression of the MT-hGHRH transgene in p27+/7 and p277/7 mice resulted in a further increase in organ growth with synergistic eects (interaction; P50.01) observed in the pituitary, liver and spleen (Figure 2 ). The most dramatic change in hGHRHinduced allometric growth occurred in the pituitaries of p27+/7 and p277/7 mice which were 312+54 and 547+48% of wildtype values, respectively (P50.001). In contrast to p27 de®ciency, reduction or elimination of p53 did not aect hGHRH-induced enlargement of the pituitary, liver or spleen (Table 2) . Therefore, further investigations focused on the eects of hGHRH expression in p27-de®cient mice.
Pituitary morphology and histology
Histologic evaluation of pituitaries from p27-de®cient mice that expressed the MT-hGHRH transgene revealed the marked increase in size was primarily due to the enlargement of the anterior lobe (Figure 3a ; H&E). Anterior lobe expansion could be attributed to Figure 1 Growth curves of male and female mice generated from crossbreeding MT-hGHRH and p27-de®cient strains. Animals were weaned at 4 weeks and genotypes were determined by PCR p27 inhibits hGHRH-induced somatotropinomas LT Teixeira et al hyperplasia of somatotropes (Figure 3a ; GH), while the density of corticotropes (Figure 3a ; ACTH), lactotropes and thyrotropes was decreased (data not shown). Consistent with previous reports (Nakayama et al., 1996; Kiyokawa et al., 1996; Fero et al., 1996) , p277/7 mice displayed hyperplasia of ACTH immunopositive cells of the intermediate lobe (melanotropes). Interestingly, the expression of the MThGHRH transgene in p277/7 mice was associated with a modest enhancement of intermediate lobe cell hyperplasia. Anterior lobes of p27+/+, hGHRH and p27+/7, hGHRH mice were homogeneous and composed of closely situated hypertrophic pituitary cells which formed branching cords (trabecular structures) similar to that observed in normal pituitary glands (data not shown). In contrast, anterior lobes of p277/7, hGHRH mice were enlarged and the tissue architecture was heterogeneous (Figure 3b , left and center panels). As in p27-intact mice, there were areas of closely packed pituitary cells in addition to areas that had lost cellularity, resembling pseudo-alveolar and pseudocystic formations. These structures were classi®ed as nodular hyperplasia characteristic of early stage adenoma development. To con®rm that the cells in these areas of nodular hyperplasia were in an advanced stage of clonal evolution their proliferative activity was compared with those of the surrounding parenchyma. p27+/+, hGHRH and p27+/7, hGHRH mice injected with BrdU to label proliferating cells showed an increase in the relative number of BrdU immunopositive pituitary cells compared to wildtype littermates, where BrdU labeled cells were infrequently found scattered randomly throughout the anterior lobe (data not shown). In contrast, pituitaries of p277/7 mice that expressed the MT-hGHRH transgene contained multiple BrdU immunopositive foci within the areas of the anterior lobe that had lost normal pituitary cytoarchitecture (Figure 3b , left and center panels). Within these foci, approximately 10% of the cells stained positive for BrdU (Figure 3b, right panel) .
In this study, all p277/7, hGHRH mice were sacri®ced at 10 ± 12 weeks. However, a subset of p27+/7, hGHRH mice were maintained for further evaluation. It was necessary to sacri®ce 50% of these mice between 6 ± 8 months of age due to rapid weight loss, lethargy and ataxia typical of pituitary mass eects. Post mortem evaluation revealed pituitary adenomas of 100 ± 200 mg in size, which were characterized by raised clustered nodules, hemorrhage, compression of the optic chiasm and hypothalamus ( Figure 3c ). Examination of the six remaining healthy appearing p27+/7, hGHRH mice showed four with neoplastic pituitaries of 4100 mg in size, while two had hyperplastic pituitaries with no macroscopic signs of neoplasia. In contrast, none of the p27-intact mice that expressed the MT-hGHRH transgene showed evidence of pituitary adenomas between 6 ± 8 months of age. Their pituitaries were enlarged (two to ®ve times that of wildtype controls) but retained normal pituitary morphology (data not shown). hGHRHinduced macroscopic pituitary adenomas did not appear in p27-intact mice until 10 months of age and exhibited a prevalence of only 33% between 10 ± 14 months (Table 3) .
Serum hormone levels
The enlarged pituitaries of p277/7, hGHRH mice (10 ± 12 weeks of age) correlated with a signi®cant increase in circulating GH concentrations, as compared to p27+/+, hGHRH and p27+/7, hGHRH mice (P50.05; Figure 4 ). Despite the increase in circulating GH levels, IGF-I levels of p277/7, hGHRH mice did not dier from those of p27+/+, hGHRH or p27+/ 7, hGHRH mice, which were 180% of nontransgenic values (295+53 ng/ml, data not shown). In addition, genotype did not aect serum prolactin levels in male mice. However, expression of the MT-hGHRH transgene in female mice resulted in hyperprolactinemia independent of p27 status (MT-hGHRH transgenics, 62.7+17.4 ng/ml vs nontransgenics, 6.6+3.0 ng/ml; P50.05, data not shown).
Female reproductive organs
With the exception of pituitary adenomas, no other macroscopic tumors were observed, regardless of p53, p27 or MT-hGHRH transgene status. However, all three female p277/7, hGHRH mice, displayed persistent abdominal enlargement, starting at *8 weeks of age which resembled that of the latter stages of pregnancy. Post mortem evaluation (12 weeks) revealed uterine horns that were engorged with¯uid. Histological examination of the uterine wall showed hyperplasia of the endometrial lining which invaded the myometrium with an in®ltration of lymphocytes (data not shown). In contrast, uteri from p277/7 and p27+/+, hGHRH mice appeared normal. The ovaries of the p277/7, hGHRH mice were larger than those of the other genotypes tested (Table 1B) and contained numerous antral follicles with no signs of corpora lutea (data not shown), similar to the ovarian phenotype observed in p277/7 mice (Kiyokawa et al., 1996; Tong et al., 1998) .
Discussion
MT-hGHRH mice express the hGHRH transgene in most tissues, including the pituitary and hypothalamus (Mayo et al., 1988; Brar et al., 1989; Frohman et al., 1990) , with circulating hGHRH levels averaging 100 ng/ml (Frohman et al., 1990) . As a consequence of excessive GHRH production, GH and IGF-I levels are elevated and body weights are 30 ± 60% greater than wildtype littermates. Chronic hGHRH exposure also leads to pituitary enlargement due to selective somatotrope hyperplasia where microadenomas are observed as early as 8 ± 10 months of age (Lloyd et al., 1992; Asa et al., 1990) . By 10 ± 14 months of age, 30 ± 40% of MT-hGHRH mice develop GH-producing macroadenomas and death occurs due to pituitary mass eects. Here we demonstrate that a reduction or complete elimination of p27 enhances the hyperplastic eects of the MT-hGHRH transgene, leading to earlier onset (6 ± 8 months vs 10 ± 14 months) and increased penetrance (80% vs 30 ± 40%) of pituitary macroadenomas. These results indicate that endogenous p27 serves to protect pituitary somatotropes against the proliferative and tumorigenic actions of excessive GHRH. These results also reveal that the tumor suppressive actions of p27 within the pituitary are dose-dependent. This is in sharp contrast to the classic de®nition of a tumor suppressor gene in which elimination of both alleles (either by mutation or somatic loss) is required for tumor formation (Knudson, 1971 ). The present study, taken together with previous reports of diminished p27 protein levels in human pituitary adenomas Bamberger et al., 1999a; Lidhar et al., 1999) , indicates a reduction in p27 levels can contribute to The stimulatory action of GHRH on pituitary GH secretion and somatotrope proliferation is thought to be mediated through ligand/receptor activation of the guanine nucleotide binding protein, G Sa , which in turn activates the adenylyl cyclase-cAMP intracellular signal transduction pathway (Harwood et al., 1984; Bilezikjian et al., 1987) . This is supported by the fact that mice expressing the rat GH promoter-driven, cholera toxin transgene (rGH-CT), which constitutively activates G Sa , have enlarged pituitaries due to somatotrope hyperplasia (Burton et al., 1991) . With advancing age (10 ± 14 months), rGH-CT mice develop pituitary adenomas (Frank Burton personal communication), mirroring the pituitary phenotype observed in MThGHRH mice. Further evidence to support a role for adenylyl cyclase-cAMP in abnormal somatotrope proliferation is the observation that *40% of all human GH-producing adenomas express a constitutively active form of G Sa (gsp) which chronically activates adenylyl cyclase and raises intracellular cAMP levels thereby activating protein kinase A (PKA; Asa and Ezzat, 1998) . The activated catalytic subunit of PKA translocates to the nucleus and phosphorylates cAMP-response element binding protein (CREB) which binds to and transactivates genes containing cAMP response elements (CREs [Meyer and Habener, 1993] ). Genes that include CREs within their promoter regions and which are activated in the pituitary following either ligand-GHRH-R generated cAMP, direct stimulation of adenylyl cyclase with forskolin, or by treatment with dbcAMP include the pituitary speci®c genes, GHRH-R (Miller and Mayo, 1997; Miller et al., 1999) , GH (Copp and Samuels, 1989; Dana and Karin, 1989) and pit-1 (GHF-1 [Soto et al., 1995] ), in addition to the general cell transcription factors, c-fos (Billestrup et al., 1987) and cAMP response element modulator (CREM [Meyer and Habener, 1993] ). To date, it is not clear which if any of these cAMP-inducible genes are direct mediators of GHRH-stimulated somatotrope hyperplasia. However, antisense oligonucleotide blockade of pit-1 translation inhibits proliferation of GC cells, a GH-producing rat pituitary cell line (Castrillo et al., 1991) , suggesting this developmentally important transcription factor (Lin et al., 1993) could act as an oncogene in cAMP-mediated pituitary tumorigenesis.
The question arises: how does p27 act to restrain GHRH-induced somatotrope proliferation? Cells progress from G1 to the S phase of the cell cycle by activation of cyclin/CDK complexes which phosphorylate and inactivate Rb, releasing E2F-DP transcription factor complexes that regulate genes essential for DNA replication (Hengstschlager et al., 1999; Dyson, 1998; Lavia and Janssen-Durr, 1999) . It is well documented that p27 restricts entry of cells into S phase by binding and inhibiting the activity of cyclin/ CDK complexes Sherr and Roberts, 1999) . Overexpression of p27 blocks cells in G1 while suppression of p27 mRNA translation by antisense oligonucleotides maintains cells in a proliferative state (Coats et al., 1996; Rivard et al., 1996) . Although p27 protein levels clearly¯uctuate during progression through the cell cycle, p27 mRNA levels remain relatively constant (Hengst and Reed, 1996) . Likewise, in the majority of human neoplasias, including pituitary adenomas, p27 mRNA levels do not dier from those observed in normal tissue, while p27 protein levels are reduced (Tanaka et al., 1997; Takeuchi et al., 1998; Dahia et al., 1998; Lloyd et al., 1997; Jin et al., 1997; Bamberger et al., 1999a; Lidhar et al., 1999; Tsihlias et al., 1999) . Taken together these observations suggest that the primary regulation of p27 levels is post-transcriptional and that a defect in this process, which might include a decrease in p27 protein synthesis or an increase in p27 protein degradation, may contribute to neoplastic transformation. The latter possibility is favored by the fact that the reduced p27 protein level, observed in proliferating cells, is associated with an increase in p27 phosphorylation and subsequent ubiquitination, suggesting p27 is targeted to the proteasome for degradation (Pagano et al., 1995; Vlach et al., 1997) .
Evidence implicating the cAMP signal transduction pathway in p27-mediated cell cycle progression has been generated using the rat follicular thyroid cell line, FRTL, which like somatotropes, proliferate in response to ligand (TSH) activation of G sa -protein coupled receptors. Treatment of FRTL cells with TSH increases intracellular cAMP, decreases p27, and increases cyclin D1 protein levels, while somatostatin, which inactivates adenylyl cyclase via G ia , reverses this eect (Medina et al., 1999) . These observations suggest that intracellular cAMP can mediate the proliferation of thyroid cells by altering the balance between cyclin/CDK complexes and their inhibitors. cAMP-mediated increases in cyclin levels and concomitant decreases in p27 levels have also been reported in granulosa cells (Robker and Richards, 1998) and the mouse ®broblast cell line, Swiss 3T3 (Mann et al., 1997) . Recent evidence suggests that the stability of p27 is dictated by its relative molar concentration with cyclin/CDK complexes. At high molar ratios, free cyclin E/CDK2 can phosphorylate p27 bound to cyclin E/CDK2, thus targeting p27 for destruction (Xu et al., 1999) . Therefore, cAMP-mediated decreases in thyroid p27 protein levels might be indirectly regulated by increases in cyclin/CDK complexes. In contrast to the stimulatory eects of cAMP on proliferation of thyrocytes and somatotropes, cAMP has been shown to inhibit the proliferation of the majority of cell types examined. Speci®cally, p27 has been implicated in cAMP-induced cell cycle arrest of macrophages, where cAMP blocks the proliferative actions of colony stimulating factor by increasing p27 levels (Kato et al., 1994) . It remains to be determined if similar or unique mechanisms govern cAMP-mediated proliferation of pituitary somatotropes.
Although this study was speci®cally designed to determine if p27 plays an inhibitory role in hGHRHinduced pituitary tumor formation, the p27-de®cient, MT-hGHRH transgenic mouse also provides insight into the role of p27 in the regulation of systemic tissue growth and dierentiation in the presence of elevated circulating growth factors. The massive increase in pituitary size observed in male MT-hGHRH mice corresponded to a twofold increase in circulating GH levels in p27+/+, hGHRH and p27+/7, hGHRH mice and a sevenfold increase in p277/7, hGHRH mice, when compared to mice not expressing the MThGHRH transgene. These results support those of our Figure 3 (a) Hematoxylin/eosin (H&E) and immunocytochemical staining for GH and ACTH of pituitary sections from p27-de®cient (+/7 and 7/7) mice with and without MT-hGHRH transgene (3 months). Pituitaries were ®xed in neutral buered formalin and paran embedded. Five mm adjacent sections were deparanized and stained with H&E or incubated with primary antisera against GH or ACTH. Antisera binding was detected using standard avidin/biotin/peroxidase immunocytochemistry. The ACTH antiserum is speci®c for products of the POMC gene and therefore stains both corticotropes within the anterior lobe and melanotropes within the intermediate lobe. Bar=1 mm. (b) Immunocytochemical staining for bromodeoxuridine (BrdU) in pituitary sections from a p277/7, hGHRH mouse (3 months). BrdU was injected (50 mg/kg, i.p.) 2 h prior to sacri®ce. BrdU is incorporated into genomic DNA in place of thymine during the S phase of the cell cycle. The panel on the left shows a pituitary section stained with H&E with two foci outlined in black (bar=1 mm). The center panel is an adjacent section, at the same magni®cation, where multiple cells within the foci stain positive for BrdU. The panel on the right is a higher magni®cation (bar=100 mm) of BrdU-immunocytochemical studies that demonstrated the increase in pituitary size of MT-hGHRH-expressing mice was due primarily to the expansion of the somatotrope population. Serum IGF-I levels were also elevated in MT-hGHRH mice, consistent with the fact that GH directly stimulates IGF-I synthesis. The liver and spleen of p277/7, hGHRH mice were disproportionately enlarged compared to those of p27+/+, hGHRH and p27+/7, hGHRH mice. The enlarged livers are likely due to a direct stimulatory action of GH, in that MT-bGH transgenic mice, but not MT-IGF-I mice, have enlarged livers characterized by hepatocyte hyperplasia and hypertrophy (Quaife et al., 1989) . In fact, sustained GH stimulation in MToGH mice can lead to hepatic carcinomas (Snibson et al., 1999) . In contrast, disproportionate growth of the spleen is likely due to secondary elevations in IGF-I, since MT-IGF-I transgenic mice, as well as MT-bGH mice, display splenic hyperplasia (Mathews et al., 1988; Blazar et al., 1995) . The synergistic eect of hGHRH transgene expression and p27-de®ciency on liver and spleen growth suggests that p27 plays a tissue speci®c role in mediating growth factor-stimulated cell proliferation.
A phenotypic characteristic unique to p277/7, hGHRH mice is that of the¯uid ®lled uterus with histologic features of adenomyosis, i.e. endometrial cell hyperplasia that invades the myometrium. Several factors may have contributed to this phenotype. First, females that express the MT-hGHRH transgene were found to be hyperprolactinemic, and persistent hyperprolactinemia generated by pituitary adenomas or by placing a pituitary isograph in the uterine horn can cause adenomyosis in the rodent (Mori et al., 1998) . In addition to the stimulatory actions of prolactin, IGF-I which is elevated in MT-hGHRH mice, has also been shown to stimulate endometrial cell proliferation in vitro (Rutanen, 1998) . Finally, the enlarged ovaries of the p277/7, hGHRH are ®lled with antral follicles without corpora lutea, similar to the ovarian phenotype reported in the p277/7 mouse (Kiyokawa et al., 1996; Tong et al., 1998) . Since chronic estrogen stimulation can lead to endometrial cell hyperplasia, a constant estrogen environment uninterrupted by luteal progesterone could exacerbate the uterine phenotype. The fact that MT-hGHRH transgenic mice with intact p27 were hyperprolactinemic and had elevated GH and IGF-I levels but normal uterine histologic features suggest that p27 protects endometrial cells from growth factor stimulation (prolactin, IGF-I and/or estrogen). This hypothesis is consistent with the fact that the p27 protein is not detectable in hyperplastic and neoplastic endometrial tissue (Bamberger et al., 1999b) but can be induced by medroxyprogesterone acetate, a treatment that also suppresses endometrial cell proliferation (Shiozawa et al., 1998) .
In this study we also examined the potential role of p53 in GHRH-induced somatotrope hyperplasia. p53, which is activated by cell stressors, metabolic changes, cytokines and growth and adhesion factors has been linked to cyclin/CDK mediated G1/S transition by its ability to activate p21, a cyclin dependent kinase inhibitor that, like p27, binds to and inactivates cyclin/CDK complexes and blocks cells in G1 (Levine, 1997; Prives and Hall, 1999) . p53 also induces apoptosis (Levine, 1997; Prives and Hall, 1999) . Mutations in the p53 gene, most commonly resulting in production of a protein with dominant negative activity, are found in more than 50% of all human cancers (Donehower, 1996) . However, p53 gene alterations appear to be rare events in human pituitary adenomas (Levy et al., 1994; Herman et al., 1993) . In fact, p53 immunostaining (presumably the wildtype protein) is immunodetectable in a subset of invasive human pituitary adenomas while normal pituitary and noninvasive adenomas are immunonegative (Blevins et al., 1998; Green et al., 1997; Thapar et al., 1996) . Therefore, upregulation of p53 expression in aggressive pituitary tumors could be a protective mechanism to guard against advancing neoplastic outgrowth. However, in this study, the reduction or absence of p53 did not eect the pituitary phenotype of 8 ± 10 week old MT-hGHRH mice, indicating p53 is not an important mediator of cAMP-induced somatotrope hyperplasia. Nonetheless, we cannot exclude the possibility that p53 may be important in the subsequent transformation of the somatotrope population from the hyperplastic to the neoplastic state.
In summary, examination of pituitary growth and histology of p27-de®cient mice that express the MThGHRH transgene clearly demonstrates that p27 plays an important role in restraining aberrant somatotrope proliferation induced by excess GHRH stimulation. These results also suggest partial reduction in p27 levels could sensitize the pituitary to secondary tumor promoters, thereby augmenting anterior pituitary oncogenesis. In addition, examination of growth labeled cells within a foci. AL, anterior lobe; IL, intermediate lobe; PL, posterior lobe. (c) H&E staining of a pituitary section taken from a p27+/7, hGHRH female mouse at 6 months of age. The image is a montage created by merging photographs taken from dierent parts of the same section. The animal from which this pituitary was taken was sacri®ced due to rapid weight loss, lethargy and ataxia, typical of pituitary enlargement. The pituitary weighed 248 mg. Bar=1 mm Figure 4 Serum GH and IGF-I levels of p27+/+, p27+/7 and p277/7 mice which expressed the hGHRH transgene. Trunk blood was collected at sacri®ce and serum GH and IGF-I concentrations determined by radioimmunoassay. Both GH and IGF-I levels were greater in MT-hGHRH transgenic mice than in nontransgenic controls (GH, 63+35 ng/ml; IGF-I, 295+53 ng/ ml). *, indicates a value that was dierent from p27+/+, hGHRH (P50.05) patterns and organ weights in p27-de®cient, MThGHRH transgenic mice indicate that p27 plays a tissue speci®c role in mediating pituitary dependent, growth factor-stimulated, tissue growth. Therefore, this hybrid mouse line provides an excellent model to study not only the progression of pituitary adenoma formation but also the role of p27 in cell speci®c proliferation and dierentiation mediated by growth factor stimulation.
Materials and methods
Animals and tissue collection
In order to vary expression of p27 in MT-hGHRH mice, heterozygous (+/7) MT-hGHRH mice were crossbred with p27+/7 mice for two successive generations to produce p27+/+, p27+/7 and p277/7 mice, half of which expressed the MT-hGHRH transgene. The MT-hGHRH mouse strain (C57BL/66SJL background) were progeny of the founder line 765-2 (two copies/allele) originally developed by Hammer et al. (1985) while the p27-de®cient mouse strain (1296C57BL/6 background) was generated by Kiyokawa et al. (1996) . A similar strategy was used to develop MThGHRH transgenic mice with heterozygote or homozygote deletion of the tumor suppressor gene, p53, using the p53-de®cient mouse strain developed by Jacks et al. (1994) ; C57BL/66129/sv background). Pups from the crossbreedings were weaned at 4 weeks and genotypes were determined by PCR of tail snip DNA (details described below). All animals were maintained on standard rodent chow diets since it has been demonstrated that the MT-hGHRH transgene is eciently expressed in most tissues of the body without heavy metal supplementation (Brar et al., 1989 (Brar et al., , 1991 . Animals were weighed weekly starting at 4 weeks, and sacri®ced by decapitation between 8 and 12 weeks. Trunk blood was taken for hormone determinations and organs (pituitary, brain, liver, spleen, kidneys, heart, testis and ovaries) were weighed. Pituitaries were ®xed in neutral buered formalin, paran embedded, and sectioned for histologic evaluation. Experiments were conducted according to the principles and procedures, outlined in the NIH Guide for the Care and Use of Laboratory Animals and all protocols were approved by the University of Illinois at Chicago Animal Care Committee. 10 min. Slides were washed in Tris HCl buered saline (TBS; pH 7.6) containing 0.01% Triton-X 100 (Sigma, St. Louis, MO, USA), treated for 30 min with 1.5% normal goat serum to block nonspeci®c binding of the second antibody, and incubated for 2 h with either monkey anti-rat GH (1 : 100 000), rabbit anti-rat PRL (1 : 20 000; Dr AF Parlow, Pituitary Hormones and Antisera Center, Harbor-UCLA Medical Center, Torrence, CA, USA), rabbit anti-rat TSH (1 : 10 000; NHPP, NIDDK) or rabbit anti-rat ACTH (1 : 10 000; NHPP, NIDDK) serum. Slides were washed in TBS/Triton and incubated for 30 min in the appropriate biotinylated secondary antiserum (1 :200, Vector Laboratories, Inc., Burlingame, CA, USA), washed in TBS and incubated an additional 30 min in avidin-peroxidase conjugate (Elite Vectastain ABC Kit Vector Laboratories). The color reaction was developed by a 5-min application of diaminobenzidine (Sigma Fast; Sigma). Sections were dehydrated in a graded series of H 2 O/ethanol/xylene and coverslips axed with Permount (Fisher Scienti®c, Pittburgh, PA, USA). Nonspeci®c binding of the secondary antisera was determined by replacing primary antisera with normal sera. Speci®city of each antiserum was determined by preabsorption. Each of these controls eliminated staining.
To label proliferating pituitary cells, a select group of animals were injected 2 h prior to sacri®ce with bromodeoxyuridine (BrdU; 50 mg/kg in saline, i.p.). Pituitaries were processed as described above and BrdU was detected by immunocytochemistry using a BrdU staining kit (Oncogene Research Products, Cambridge, MA, USA) according to the manufacturer's instructions. No staining was detected on pituitary sections where the primary antiserum was omitted or on sections from an animal that was not injected with BrdU.
Radioimmunoassays (RIAs)
Serum samples were assayed for GH using a homologous rat GH RIA (Frohman and Bernardis, 1968) which was shown to have complete crossreactivity to mouse GH. Serum PRL concentrations were determined in a homologous mouse RIA using the reagents and protocol kindly provided by Dr AF Parlow. Total serum IGF-I levels were assessed using the Nichols Diagnostics IGF-I RIA Kit following removal of the binding proteins by SepPak C18 reverse-phase cartridges (Waters, Millford, MA, USA).
Statistical analysis
Dierences in growth rates among the six genotypes generated by breeding MT-hGHRH mice to p27-or p53-de®cient mice were evaluated by the general linear models for repeated measures (SAS). Dierences between mean organ weights and serum hormone levels at the time of sacri®ce were assessed by 2-way ANOVA using Duncan's New Multiple Range test and data were log transformed where appropriate.
